NASDAQ: QUCYQuantum Cyber Nv Stock
$1.73-0.17 (-8.95%)
Updated Jun 12, 2026
Shares of quantum computing-related companies... find out Why QUCY Price Moved with a free WallStreetZen account
Why Price MovedQUCY Price
$1.73
Fair Value Price
-$1.64
Market Cap
$25.36M
52 Week Low
$0.30
52 Week High
$4.93
P/E
N/A
P/B
5.53x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.68
Operating Cash Flow
N/A
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
QUCY Overview
Mainz Biomed NV develops in-vitro human genetics tests for clinical diagnostics. Offerings offers ColoAlert, a colorectal cancer screening test, PancAlert, a product candidate for a pancreatic cancer screening test, GenoStrip to detect pathogens in environments on a molecular genetic basis, and research-use-only and IVD tests. Mainz Biomed was founded in 2008 and is headquartered in Mainz, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QUCY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
QUCY
Ranked#25 of 44
Ranked#25 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.97 | A | |
| $129.84 | B | |
| $16.19 | B |
Be the first to know about important QUCY news, forecast changes, insider trades & much more!
QUCY News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QUCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QUCY ($1.73) is overvalued by 205.71% relative to our estimate of its Fair Value price of -$1.64 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QUCY ($1.73) is not significantly undervalued (205.71%) relative to our estimate of its Fair Value price of -$1.64 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QUCY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more QUCY due diligence checks available for Premium users.
Valuation
QUCY fair value
Fair Value of QUCY stock based on Discounted Cash Flow (DCF)
Price
$1.73
Fair Value
-$1.64
Undervalued by
205.71%
QUCY ($1.73) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QUCY ($1.73) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QUCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
16.39x
Market
14.15x
QUCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.53x
Industry
3.51x
QUCY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QUCY's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.1M
Profit Margin
0%
Assets to liabilities
Assets
$7.7M
Liabilities
$3.1M
Debt to equity
0.68
QUCY's short-term assets ($6.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QUCY's short-term assets ($6.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QUCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
-$650.7k
Financing
$7.3M
QUCY vs Diagnostic & Research Stocks
Quantum Cyber Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.